{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 137,
  "pageCount": 239,
  "prevPage": 136,
  "nextPage": 138,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses expert quotes to undermine the company's product strategy.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/137",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-137",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The uniformity of negative comments suggests that an Omnia-fueled turnaround is a delusion.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-37b66c160222",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "list",
      "text": "A KOL who still uses Nevro as 25% of his device mix described Omnia as “nothing special” and me-too",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14bcc7e8-a5e9-4825-a895-509b99968407",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "Omnia is just an attempt to “salvage the company” after doctors began to abandon high frequency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "768b022f-994f-4d52-b1de-c5914355568a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Doctors have no reason to use Omnia’s low-frequency option versus current low-frequency devices",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c0ec29c-0ffa-4858-ba2d-6126d572d468",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "The uniformity of negative comments suggests that an Omnia-fueled turnaround is a delusion.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ed31060-6e74-4b62-ac3c-e895c6915c5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.1,
        "y": 0.7
      },
      "kind": "quote",
      "text": "Abbott came out with a device you don't ever have to recharge for 10 years... If the high frequency doesn't work, why would you use their low frequency device over someone else's?",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00c92d22-1f58-4cd6-a2f9-875569751f20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.1,
        "y": 0.5
      },
      "kind": "quote",
      "text": "Omni's not a game-changer. The rest of the world moved on from Nevro so Omnia is just using the low-frequency therapy Nevro claimed they were better than, to salvage the company.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75ffdc7b-379c-42c9-adfb-2785ddde6572",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.1,
        "y": 0.25
      },
      "kind": "quote",
      "text": "To tell you the truth, I was always relatively pessimistic on Nevro... what they're doing is nothing special, that's the bottom line. They're coming around to every other company which says that you need to offer everything.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fffd543-195b-465a-9f7e-8ce28062a822",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"To tell you the truth, I was always relatively pessimistic on Nevro. In fact, I had to write an article in one of the journals a few years ago saying that Nevro will not last unless they provide other waveforms and the company wrote nasty letters back to me because I believed even at that time that it's not a one-size-fits-all. What they're doing with Omnia - what they're doing is nothing special, that's the bottom line. They're coming around to every other company which says that you need to offer everything. I don't consider this a gamechanger at all. Omnia is nothing dramatic. That Nevro has come out with this is not earth-shattering.\" — High volume implanter; \"Omni's not a game-changer. The rest of the world moved on from Nevro so Omnia is just using the low-frequency therapy Nevro claimed they were better than, to salvage the company. But you could do low frequency with Abbott, Medtronic, or Boston Scientific, and you have a device that's MRI compatible and one you don't have to recharge.\" — KOL and former high volume Nevro user; \"Abbott came out with a device you don't ever have to recharge for 10 years, or you implant Medtronic and it's MRI compatible. If the high frequency doesn't work, why would you use their low frequency device over someone else's? Nevro's entire campaign at launch was about how much better they were than low frequency, but now they're using low frequency to salvage themselves.\" — KOL and former high volume Nevro user",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b342-3822c5778fad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26507b79-7e7c-48a9-8e96-366fba515815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "10. The new Omnia stimulator, the centerpiece of Nevro's turnaround hopes, is a Hail Mary and colossal flop",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5519073d-5dcd-46c6-888b-8d2196111843",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "284798c0-826a-4688-a834-dba516a48fb7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "f36fabda-f1f5-4422-ba96-bbbe8ebc6eee",
      "evidence": "Frames Nevro's product as a 'colossal flop' and 'delusion' to build a case against the company.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}